「with the」の検索結果
143件：101～105件目を表示
-
Management Policy | About Senju | SENJU Pharmaceutical
ecessary and valuable for society, we are committed to pursuing happiness for all people associated with Senju rather than just becoming a “big company” that pursues only greater growth and increased ...
http://www.senju.co.jp/english/about/philosophy.html -
pan as of December 22, 2025. Avarept® Ophthalmic suspension 0.3% represents a novel therapy for DED with Transient Receptor Potential cation channel subfamily V member 1 (TRPV1)*1 antagonist, designed...
https://www.senju.co.jp/system/files/content_news/2025-12/ENG_20251222_0.pdf -
pan as of December 22, 2025. Avarept® Ophthalmic suspension 0.3% represents a novel therapy for DED with Transient Receptor Potential cation channel subfamily V member 1 (TRPV1)*1 antagonist, designed...
https://www.senju.co.jp/system/files/content_news/2025-12/ENG_20251222.pdf -
ry Eye Disease (DED), has been launched in Japan today. Avarept® represents a novel therapy for DED with Transient Receptor Potential cation channel subfamily V member 1 (TRPV1) *1 antagonist, designe...
https://www.senju.co.jp/system/files/content_news/2026-04/ENG_20260406.pdf -
ry Eye Disease (DED), has been launched in Japan today. Avarept® represents a novel therapy for DED with Transient Receptor Potential cation channel subfamily V member 1 (TRPV1) *1 antagonist, designe...
https://www.senju.co.jp/system/files/content_news/2026-04/ENG_20260406_0.pdf